Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia.
Jayastu SenapatiMahran ShoukierGuillermo Garcia ManeroXuemei WangKeyur PatelTapan Mahendra KadiaFarhad RavandiNaveen PemmarajuMaro Ohanian DONaval G DaverCourtney D D DiNardoYesid AlvaradoJeffrey AldrichGautam BorthakurPublished in: American journal of hematology (2022)
DAC is an effective maintenance therapy for CBF-AML patients with persistent fusion transcript at a low level after FLAG-based regimen. Attainment of CMR with DAC maintenance can lead to long-term remission in patients who have persistent MRD positive after FLAG-based regimen or are unable to receive the full course of consolidation therapy.
Keyphrases
- acute myeloid leukemia
- end stage renal disease
- allogeneic hematopoietic stem cell transplantation
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- patient reported outcomes
- stem cells
- rheumatoid arthritis
- systemic lupus erythematosus
- acute lymphoblastic leukemia
- single cell